Swiss drugmaker Idorsia (SIX: IDIA) has announced the publication of a Phase IV study in the Journal of Sleep Research.
The study, named A randomized cross-over trial of daridorexant for the treatment of chronic insomnia and nocturia, is a reminder of the efficacy of Quviviq (daridorexant), in patients with chronic insomnia and nocturia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze